AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
pyrazinamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2328 | 98-96-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A pyrazine that is used therapeutically as an antitubercular agent.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 15 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1.60 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 243.67 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.634 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.573 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 55.847 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.753 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 86.240 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 90.140 | % | High | 1 |
| herg | hERG pIC50 | 3.393 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.056 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.192 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 79.810 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,IRAK1,ITK,JAK1,MAP3K21,MAPK7,MARK4,PDK2,PDK4,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,ULK1 | 33 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,PRKDC | 4 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.499 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.656 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.762 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 93.520 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.054 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 85.190 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 2.547 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 0.532 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 97.380 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 79.060 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 508.159 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 3, 1971 | FDA | DAVA PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug reaction with eosinophilia and systemic symptoms | 1104.09 | 25.25 | 344 | 10820 | 42414 | 90574869 |
| Paradoxical drug reaction | 735.85 | 25.25 | 165 | 10999 | 5601 | 90611682 |
| Drug resistance | 415.43 | 25.25 | 152 | 11012 | 30297 | 90586986 |
| Drug-induced liver injury | 413.96 | 25.25 | 208 | 10956 | 90110 | 90527173 |
| Acute hepatic failure | 388.90 | 25.25 | 134 | 11030 | 22427 | 90594856 |
| Immune reconstitution inflammatory syndrome | 366.87 | 25.25 | 98 | 11066 | 6921 | 90610362 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 332.19 | 25.25 | 57 | 11107 | 446 | 90616837 |
| Tuberculoma of central nervous system | 292.92 | 25.25 | 49 | 11115 | 323 | 90616960 |
| Hepatotoxicity | 265.33 | 25.25 | 124 | 11040 | 45718 | 90571565 |
| Drug interaction | 220.44 | 25.25 | 217 | 10947 | 276236 | 90341047 |
| Hepatitis | 170.49 | 25.25 | 107 | 11057 | 70632 | 90546651 |
| Tuberculosis | 168.59 | 25.25 | 62 | 11102 | 12487 | 90604796 |
| Pulmonary tuberculosis | 163.40 | 25.25 | 48 | 11116 | 4786 | 90612497 |
| Jaundice | 160.82 | 25.25 | 79 | 11085 | 32438 | 90584845 |
| Hepatic encephalopathy | 131.23 | 25.25 | 53 | 11111 | 13719 | 90603564 |
| Disseminated tuberculosis | 130.39 | 25.25 | 37 | 11127 | 3262 | 90614021 |
| Neuropathy peripheral | 121.10 | 25.25 | 114 | 11050 | 136856 | 90480427 |
| Hypertransaminasaemia | 92.05 | 25.25 | 43 | 11121 | 15782 | 90601501 |
| Eosinophilia | 91.72 | 25.25 | 52 | 11112 | 28481 | 90588802 |
| Pyrexia | 85.14 | 25.25 | 224 | 10940 | 660261 | 89957022 |
| Pancreatitis haemorrhagic | 85.04 | 25.25 | 19 | 11145 | 630 | 90616653 |
| Alanine aminotransferase increased | 85.03 | 25.25 | 88 | 11076 | 118250 | 90499033 |
| Aspartate aminotransferase increased | 78.40 | 25.25 | 79 | 11085 | 102858 | 90514425 |
| Meningitis tuberculous | 73.97 | 25.25 | 17 | 11147 | 641 | 90616642 |
| Lymphadenopathy | 73.75 | 25.25 | 54 | 11110 | 45721 | 90571562 |
| Electrocardiogram QT prolonged | 71.14 | 25.25 | 64 | 11100 | 72392 | 90544891 |
| Drug level decreased | 67.84 | 25.25 | 30 | 11134 | 9700 | 90607583 |
| Transaminases increased | 64.76 | 25.25 | 46 | 11118 | 37146 | 90580137 |
| Multiple organ dysfunction syndrome | 60.55 | 25.25 | 57 | 11107 | 68279 | 90549004 |
| Hepatocellular injury | 57.90 | 25.25 | 39 | 11125 | 28919 | 90588364 |
| Hepatitis toxic | 55.97 | 25.25 | 20 | 11144 | 3705 | 90613578 |
| Multiple-drug resistance | 54.29 | 25.25 | 24 | 11140 | 7752 | 90609531 |
| Rash maculo-papular | 54.27 | 25.25 | 43 | 11121 | 40890 | 90576393 |
| Hepatic function abnormal | 53.74 | 25.25 | 45 | 11119 | 46243 | 90571040 |
| Pain | 52.29 | 25.25 | 29 | 11135 | 996312 | 89620971 |
| Fatigue | 51.91 | 25.25 | 40 | 11124 | 1153983 | 89463300 |
| Distributive shock | 50.00 | 25.25 | 18 | 11146 | 3406 | 90613877 |
| Aspergillus infection | 49.64 | 25.25 | 25 | 11139 | 10798 | 90606485 |
| Hepatic failure | 48.99 | 25.25 | 40 | 11124 | 39688 | 90577595 |
| Anaemia | 47.67 | 25.25 | 122 | 11042 | 352680 | 90264603 |
| Hepatitis fulminant | 47.52 | 25.25 | 18 | 11146 | 3927 | 90613356 |
| Oedematous kidney | 46.37 | 25.25 | 9 | 11155 | 147 | 90617136 |
| Gamma-glutamyltransferase increased | 46.35 | 25.25 | 38 | 11126 | 37914 | 90579369 |
| Psychotic disorder | 46.17 | 25.25 | 35 | 11129 | 31195 | 90586088 |
| Fall | 44.70 | 25.25 | 4 | 11160 | 481806 | 90135477 |
| Hyperuricaemia | 44.54 | 25.25 | 20 | 11144 | 6699 | 90610584 |
| Optic neuropathy | 42.49 | 25.25 | 15 | 11149 | 2683 | 90614600 |
| Joint swelling | 42.13 | 25.25 | 6 | 11158 | 503294 | 90113989 |
| Toxic optic neuropathy | 41.99 | 25.25 | 9 | 11155 | 245 | 90617038 |
| Oedematous pancreatitis | 41.18 | 25.25 | 11 | 11153 | 774 | 90616509 |
| Immunosuppressant drug level decreased | 41.15 | 25.25 | 12 | 11152 | 1164 | 90616119 |
| Cholestatic liver injury | 41.00 | 25.25 | 16 | 11148 | 3781 | 90613502 |
| Lymph node tuberculosis | 40.66 | 25.25 | 11 | 11153 | 812 | 90616471 |
| Optic neuritis | 40.45 | 25.25 | 21 | 11143 | 9657 | 90607626 |
| Rash morbilliform | 40.08 | 25.25 | 16 | 11148 | 4013 | 90613270 |
| Respiratory failure | 39.53 | 25.25 | 60 | 11104 | 118358 | 90498925 |
| Hyperbilirubinaemia | 38.42 | 25.25 | 23 | 11141 | 13913 | 90603370 |
| Tuberculosis gastrointestinal | 37.79 | 25.25 | 9 | 11155 | 397 | 90616886 |
| Shock | 37.65 | 25.25 | 30 | 11134 | 28748 | 90588535 |
| Vomiting | 37.09 | 25.25 | 193 | 10971 | 788100 | 89829183 |
| Liver transplant | 36.94 | 25.25 | 13 | 11151 | 2304 | 90614979 |
| Hydrocephalus | 36.80 | 25.25 | 17 | 11147 | 6077 | 90611206 |
| Neurotoxicity | 36.10 | 25.25 | 26 | 11138 | 21441 | 90595842 |
| Swelling | 35.05 | 25.25 | 5 | 11159 | 419053 | 90198230 |
| Peritoneal tuberculosis | 34.82 | 25.25 | 9 | 11155 | 557 | 90616726 |
| Coagulopathy | 34.20 | 25.25 | 26 | 11138 | 23263 | 90594020 |
| Arthropathy | 34.06 | 25.25 | 3 | 11161 | 366239 | 90251044 |
| Hepatic necrosis | 32.88 | 25.25 | 16 | 11148 | 6422 | 90610861 |
| Exposure during pregnancy | 32.73 | 25.25 | 83 | 11081 | 238327 | 90378956 |
| Pathogen resistance | 32.18 | 25.25 | 17 | 11147 | 8098 | 90609185 |
| Peripheral swelling | 32.15 | 25.25 | 6 | 11158 | 413100 | 90204183 |
| Pulmonary toxicity | 31.71 | 25.25 | 19 | 11145 | 11512 | 90605771 |
| Sinusitis | 31.40 | 25.25 | 3 | 11161 | 343085 | 90274198 |
| Immune system disorder | 31.15 | 25.25 | 19 | 11145 | 11886 | 90605397 |
| Infection | 31.03 | 25.25 | 4 | 11160 | 362090 | 90255193 |
| Pain in extremity | 30.22 | 25.25 | 9 | 11155 | 450520 | 90166763 |
| Herbal toxicity | 30.14 | 25.25 | 5 | 11159 | 31 | 90617252 |
| Hepatosplenomegaly | 30.11 | 25.25 | 12 | 11152 | 2997 | 90614286 |
| Premature delivery | 29.94 | 25.25 | 30 | 11134 | 38732 | 90578551 |
| Synovitis | 29.87 | 25.25 | 3 | 11161 | 329749 | 90287534 |
| Polyneuropathy | 29.30 | 25.25 | 22 | 11142 | 19319 | 90597964 |
| Rheumatoid arthritis | 28.79 | 25.25 | 5 | 11159 | 362609 | 90254674 |
| Abdominal discomfort | 27.83 | 25.25 | 12 | 11152 | 477316 | 90139967 |
| Infectious pleural effusion | 27.66 | 25.25 | 10 | 11154 | 1915 | 90615368 |
| Granuloma | 27.52 | 25.25 | 14 | 11150 | 6171 | 90611112 |
| Jarisch-Herxheimer reaction | 27.15 | 25.25 | 7 | 11157 | 429 | 90616854 |
| Mastitis bacterial | 26.97 | 25.25 | 5 | 11159 | 63 | 90617220 |
| Generalised tonic-clonic seizure | 26.93 | 25.25 | 27 | 11137 | 34876 | 90582407 |
| Granulomatous lymphadenitis | 26.09 | 25.25 | 6 | 11158 | 227 | 90617056 |
| Visual acuity reduced | 25.60 | 25.25 | 22 | 11142 | 23388 | 90593895 |
| Abdominal lymphadenopathy | 25.40 | 25.25 | 8 | 11156 | 1007 | 90616276 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 1136.30 | 20.27 | 271 | 13483 | 4467 | 42603114 |
| Immune reconstitution inflammatory syndrome | 614.84 | 20.27 | 197 | 13557 | 9946 | 42597635 |
| Drug-induced liver injury | 537.63 | 20.27 | 257 | 13497 | 38016 | 42569565 |
| Drug reaction with eosinophilia and systemic symptoms | 502.69 | 20.27 | 253 | 13501 | 41822 | 42565759 |
| Hepatotoxicity | 365.28 | 20.27 | 173 | 13581 | 24994 | 42582587 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 333.12 | 20.27 | 68 | 13686 | 513 | 42607068 |
| Drug resistance | 287.55 | 20.27 | 163 | 13591 | 34085 | 42573496 |
| Jaundice | 233.49 | 20.27 | 143 | 13611 | 34446 | 42573135 |
| Tuberculosis | 215.52 | 20.27 | 91 | 13663 | 10008 | 42597573 |
| Tuberculoma of central nervous system | 169.12 | 20.27 | 34 | 13720 | 235 | 42607346 |
| Hepatitis | 159.40 | 20.27 | 103 | 13651 | 27197 | 42580384 |
| Pulmonary tuberculosis | 132.29 | 20.27 | 54 | 13700 | 5447 | 42602134 |
| Drug interaction | 118.93 | 20.27 | 264 | 13490 | 266735 | 42340846 |
| Meningitis tuberculous | 112.93 | 20.27 | 29 | 13725 | 650 | 42606931 |
| Acute hepatic failure | 111.06 | 20.27 | 69 | 13685 | 17004 | 42590577 |
| Electrocardiogram QT prolonged | 94.94 | 20.27 | 96 | 13658 | 47849 | 42559732 |
| Disseminated tuberculosis | 93.64 | 20.27 | 35 | 13719 | 2789 | 42604792 |
| Immune system disorder | 88.93 | 20.27 | 42 | 13712 | 6002 | 42601579 |
| Tuberculosis of central nervous system | 86.78 | 20.27 | 19 | 13735 | 207 | 42607374 |
| Hydrocephalus | 79.62 | 20.27 | 39 | 13715 | 6039 | 42601542 |
| Lymphadenopathy | 77.63 | 20.27 | 73 | 13681 | 33292 | 42574289 |
| Drug level decreased | 76.97 | 20.27 | 45 | 13709 | 9932 | 42597649 |
| Multiple-drug resistance | 67.20 | 20.27 | 37 | 13717 | 7285 | 42600296 |
| Pyrexia | 65.08 | 20.27 | 275 | 13479 | 393767 | 42213814 |
| Neuropathy peripheral | 62.14 | 20.27 | 115 | 13639 | 101738 | 42505843 |
| Optic neuropathy | 61.55 | 20.27 | 25 | 13729 | 2487 | 42605094 |
| Granuloma | 53.14 | 20.27 | 26 | 13728 | 4015 | 42603566 |
| Optic neuritis | 52.53 | 20.27 | 26 | 13728 | 4116 | 42603465 |
| Lymph node tuberculosis | 52.37 | 20.27 | 15 | 13739 | 512 | 42607069 |
| Liver function test abnormal | 51.92 | 20.27 | 58 | 13696 | 32333 | 42575248 |
| Tubulointerstitial nephritis | 51.45 | 20.27 | 57 | 13697 | 31491 | 42576090 |
| Skin disorder | 51.20 | 20.27 | 43 | 13711 | 16901 | 42590680 |
| Hepatic failure | 50.70 | 20.27 | 62 | 13692 | 38038 | 42569543 |
| Alanine aminotransferase increased | 49.19 | 20.27 | 96 | 13658 | 88310 | 42519271 |
| Hepatitis fulminant | 48.11 | 20.27 | 26 | 13728 | 4933 | 42602648 |
| Eosinophilia | 47.82 | 20.27 | 56 | 13698 | 32843 | 42574738 |
| Mycobacterial infection | 46.95 | 20.27 | 21 | 13733 | 2647 | 42604934 |
| Hepatic enzyme increased | 44.69 | 20.27 | 64 | 13690 | 45720 | 42561861 |
| Diaphragmatic injury | 44.34 | 20.27 | 10 | 13744 | 126 | 42607455 |
| Granulomatous liver disease | 43.95 | 20.27 | 14 | 13740 | 689 | 42606892 |
| Pain | 42.71 | 20.27 | 13 | 13741 | 244835 | 42362746 |
| Hepatitis toxic | 41.36 | 20.27 | 19 | 13735 | 2548 | 42605033 |
| Tuberculosis of eye | 40.21 | 20.27 | 8 | 13746 | 52 | 42607529 |
| Unmasking of previously unidentified disease | 39.90 | 20.27 | 15 | 13739 | 1214 | 42606367 |
| Urinary tract inflammation | 38.36 | 20.27 | 10 | 13744 | 238 | 42607343 |
| Fall | 38.20 | 20.27 | 14 | 13740 | 234506 | 42373075 |
| Tuberculosis gastrointestinal | 38.05 | 20.27 | 10 | 13744 | 246 | 42607335 |
| Hyperuricaemia | 37.22 | 20.27 | 28 | 13726 | 9396 | 42598185 |
| Central nervous system vasculitis | 37.07 | 20.27 | 12 | 13742 | 622 | 42606959 |
| Pathogen resistance | 36.55 | 20.27 | 30 | 13724 | 11420 | 42596161 |
| Splenic embolism | 36.51 | 20.27 | 10 | 13744 | 289 | 42607292 |
| Oral candidiasis | 36.36 | 20.27 | 33 | 13721 | 14372 | 42593209 |
| Death | 34.73 | 20.27 | 62 | 13692 | 471123 | 42136458 |
| Toxic epidermal necrolysis | 34.72 | 20.27 | 43 | 13711 | 26707 | 42580874 |
| Sideroblastic anaemia | 34.48 | 20.27 | 10 | 13744 | 357 | 42607224 |
| Vitamin B1 decreased | 33.96 | 20.27 | 10 | 13744 | 377 | 42607204 |
| Transaminases increased | 33.60 | 20.27 | 47 | 13707 | 32838 | 42574743 |
| Encephalitis | 33.51 | 20.27 | 26 | 13728 | 9132 | 42598449 |
| Aspartate aminotransferase increased | 32.69 | 20.27 | 75 | 13679 | 77088 | 42530493 |
| Tuberculous pleurisy | 32.65 | 20.27 | 10 | 13744 | 432 | 42607149 |
| Condition aggravated | 32.56 | 20.27 | 168 | 13586 | 260586 | 42346995 |
| Mitochondrial neurogastrointestinal encephalopathy | 32.26 | 20.27 | 5 | 13749 | 4 | 42607577 |
| Bone tuberculosis | 32.06 | 20.27 | 10 | 13744 | 459 | 42607122 |
| Lymphopenia | 31.82 | 20.27 | 37 | 13717 | 21526 | 42586055 |
| Accelerated hypertension | 31.80 | 20.27 | 9 | 13745 | 294 | 42607287 |
| Deafness | 31.02 | 20.27 | 29 | 13725 | 13111 | 42594470 |
| Lichenoid keratosis | 30.94 | 20.27 | 18 | 13736 | 3932 | 42603649 |
| Thalamic infarction | 30.15 | 20.27 | 11 | 13743 | 818 | 42606763 |
| Product dose omission issue | 29.14 | 20.27 | 7 | 13747 | 154358 | 42453223 |
| Drug eruption | 28.21 | 20.27 | 36 | 13718 | 23039 | 42584542 |
| Mycobacterium abscessus infection | 27.33 | 20.27 | 10 | 13744 | 750 | 42606831 |
| Fatigue | 27.24 | 20.27 | 63 | 13691 | 435578 | 42172003 |
| Febrile neutropenia | 27.14 | 20.27 | 13 | 13741 | 185690 | 42421891 |
| Conductive deafness | 27.06 | 20.27 | 9 | 13745 | 508 | 42607073 |
| Splenomegaly | 26.41 | 20.27 | 30 | 13724 | 17017 | 42590564 |
| Psoas abscess | 26.27 | 20.27 | 10 | 13744 | 837 | 42606744 |
| Constipation | 25.88 | 20.27 | 10 | 13744 | 162281 | 42445300 |
| Brain oedema | 25.75 | 20.27 | 29 | 13725 | 16298 | 42591283 |
| Pulmonary granuloma | 25.73 | 20.27 | 12 | 13742 | 1665 | 42605916 |
| Atrial fibrillation | 25.07 | 20.27 | 7 | 13747 | 139586 | 42467995 |
| Rash maculo-papular | 24.93 | 20.27 | 44 | 13710 | 37459 | 42570122 |
| Blood bilirubin increased | 24.84 | 20.27 | 47 | 13707 | 42205 | 42565376 |
| Ototoxicity | 24.84 | 20.27 | 13 | 13741 | 2312 | 42605269 |
| Haemophagocytic lymphohistiocytosis | 24.79 | 20.27 | 30 | 13724 | 18192 | 42589389 |
| Immunosuppressant drug level decreased | 24.77 | 20.27 | 12 | 13742 | 1812 | 42605769 |
| Vomiting | 24.16 | 20.27 | 168 | 13586 | 289555 | 42318026 |
| Liver transplant rejection | 23.89 | 20.27 | 13 | 13741 | 2500 | 42605081 |
| Implant site infection | 23.22 | 20.27 | 10 | 13744 | 1151 | 42606430 |
| Jarisch-Herxheimer reaction | 23.19 | 20.27 | 9 | 13745 | 794 | 42606787 |
| Pulmonary sequestration | 22.87 | 20.27 | 5 | 13749 | 54 | 42607527 |
| Adrenocortical insufficiency acute | 22.57 | 20.27 | 12 | 13742 | 2203 | 42605378 |
| Malignant neoplasm progression | 22.34 | 20.27 | 4 | 13750 | 108396 | 42499185 |
| Hepatic encephalopathy | 22.25 | 20.27 | 27 | 13727 | 16415 | 42591166 |
| Marrow hyperplasia | 22.23 | 20.27 | 10 | 13744 | 1277 | 42606304 |
| Trisomy 21 | 22.20 | 20.27 | 8 | 13746 | 574 | 42607007 |
| Renal atrophy | 22.08 | 20.27 | 10 | 13744 | 1297 | 42606284 |
| Tuberculoid leprosy | 21.95 | 20.27 | 5 | 13749 | 66 | 42607515 |
| Dilatation intrahepatic duct acquired | 21.68 | 20.27 | 5 | 13749 | 70 | 42607511 |
| Anaemia | 21.32 | 20.27 | 159 | 13595 | 280119 | 42327462 |
| Cachexia | 21.30 | 20.27 | 19 | 13735 | 8085 | 42599496 |
| HIV infection | 20.86 | 20.27 | 10 | 13744 | 1475 | 42606106 |
| Hepatic function abnormal | 20.60 | 20.27 | 49 | 13705 | 51518 | 42556063 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 1772.41 | 20.00 | 415 | 23942 | 9402 | 110555540 |
| Drug reaction with eosinophilia and systemic symptoms | 1515.76 | 20.00 | 597 | 23760 | 81498 | 110483444 |
| Immune reconstitution inflammatory syndrome | 981.37 | 20.00 | 288 | 24069 | 15938 | 110549004 |
| Drug-induced liver injury | 838.47 | 20.00 | 444 | 23913 | 119623 | 110445319 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 649.07 | 20.00 | 123 | 24234 | 931 | 110564011 |
| Drug resistance | 644.09 | 20.00 | 292 | 24065 | 56082 | 110508860 |
| Hepatotoxicity | 623.56 | 20.00 | 296 | 24061 | 63104 | 110501838 |
| Acute hepatic failure | 487.52 | 20.00 | 211 | 24146 | 36257 | 110528685 |
| Tuberculoma of central nervous system | 411.41 | 20.00 | 77 | 24280 | 540 | 110564402 |
| Jaundice | 406.97 | 20.00 | 217 | 24140 | 59019 | 110505923 |
| Tuberculosis | 350.79 | 20.00 | 136 | 24221 | 17638 | 110547304 |
| Drug interaction | 327.64 | 20.00 | 472 | 23885 | 499711 | 110065231 |
| Pulmonary tuberculosis | 284.97 | 20.00 | 98 | 24259 | 9041 | 110555901 |
| Hepatitis | 241.80 | 20.00 | 182 | 24175 | 89872 | 110475070 |
| Neuropathy peripheral | 210.24 | 20.00 | 227 | 24130 | 179050 | 110385892 |
| Meningitis tuberculous | 188.76 | 20.00 | 46 | 24311 | 1232 | 110563710 |
| Disseminated tuberculosis | 175.39 | 20.00 | 59 | 24298 | 5087 | 110559855 |
| Electrocardiogram QT prolonged | 162.25 | 20.00 | 157 | 24200 | 108803 | 110456139 |
| Drug level decreased | 150.37 | 20.00 | 76 | 24281 | 18472 | 110546470 |
| Lymphadenopathy | 149.45 | 20.00 | 119 | 24238 | 63716 | 110501226 |
| Pyrexia | 145.83 | 20.00 | 481 | 23876 | 897784 | 109667158 |
| Hepatic encephalopathy | 138.36 | 20.00 | 83 | 24274 | 28173 | 110536769 |
| Eosinophilia | 133.48 | 20.00 | 107 | 24250 | 57829 | 110507113 |
| Alanine aminotransferase increased | 129.48 | 20.00 | 180 | 24177 | 183593 | 110381349 |
| Hydrocephalus | 125.49 | 20.00 | 56 | 24301 | 10319 | 110554623 |
| Immune system disorder | 123.32 | 20.00 | 60 | 24297 | 13441 | 110551501 |
| Optic neuropathy | 111.27 | 20.00 | 41 | 24316 | 4617 | 110560325 |
| Multiple-drug resistance | 106.60 | 20.00 | 54 | 24303 | 13181 | 110551761 |
| Aspartate aminotransferase increased | 102.83 | 20.00 | 150 | 24207 | 159786 | 110405156 |
| Hepatic failure | 102.19 | 20.00 | 99 | 24258 | 68640 | 110496302 |
| Pain | 99.64 | 20.00 | 43 | 24314 | 954912 | 109610030 |
| Lymph node tuberculosis | 95.73 | 20.00 | 26 | 24331 | 1078 | 110563864 |
| Tuberculosis of central nervous system | 93.10 | 20.00 | 22 | 24335 | 515 | 110564427 |
| Hepatitis toxic | 91.47 | 20.00 | 38 | 24319 | 5883 | 110559059 |
| Optic neuritis | 88.38 | 20.00 | 45 | 24312 | 11102 | 110553840 |
| Hepatitis fulminant | 87.18 | 20.00 | 41 | 24316 | 8519 | 110556423 |
| Transaminases increased | 86.25 | 20.00 | 87 | 24270 | 63303 | 110501639 |
| Hypertransaminasaemia | 85.72 | 20.00 | 58 | 24299 | 24197 | 110540745 |
| Fall | 83.32 | 20.00 | 16 | 24341 | 603466 | 109961476 |
| Pancreatitis haemorrhagic | 74.61 | 20.00 | 21 | 24336 | 995 | 110563947 |
| Hyperuricaemia | 74.56 | 20.00 | 44 | 24313 | 14487 | 110550455 |
| Rash maculo-papular | 73.23 | 20.00 | 86 | 24271 | 74136 | 110490806 |
| Granuloma | 71.44 | 20.00 | 37 | 24320 | 9453 | 110555489 |
| Tuberculosis gastrointestinal | 70.12 | 20.00 | 18 | 24339 | 598 | 110564344 |
| Fatigue | 68.90 | 20.00 | 101 | 24256 | 1215857 | 109349085 |
| Immunosuppressant drug level decreased | 64.75 | 20.00 | 24 | 24333 | 2747 | 110562195 |
| Hepatocellular injury | 64.34 | 20.00 | 67 | 24290 | 50575 | 110514367 |
| Anaemia | 63.99 | 20.00 | 264 | 24093 | 546822 | 110018120 |
| Hepatic function abnormal | 63.62 | 20.00 | 88 | 24269 | 89207 | 110475735 |
| Tubulointerstitial nephritis | 60.49 | 20.00 | 67 | 24290 | 54217 | 110510725 |
| Liver function test abnormal | 58.45 | 20.00 | 74 | 24283 | 68876 | 110496066 |
| Granulomatous liver disease | 57.31 | 20.00 | 19 | 24338 | 1565 | 110563377 |
| Pathogen resistance | 57.12 | 20.00 | 40 | 24317 | 17632 | 110547310 |
| Psychotic disorder | 56.98 | 20.00 | 63 | 24294 | 50874 | 110514068 |
| Hyperbilirubinaemia | 56.88 | 20.00 | 50 | 24307 | 30621 | 110534321 |
| Joint swelling | 56.50 | 20.00 | 14 | 24343 | 442831 | 110122111 |
| Mycobacterial infection | 53.92 | 20.00 | 24 | 24333 | 4393 | 110560549 |
| Sinusitis | 53.18 | 20.00 | 3 | 24354 | 296685 | 110268257 |
| Peripheral swelling | 53.07 | 20.00 | 12 | 24345 | 404022 | 110160920 |
| Peritoneal tuberculosis | 51.65 | 20.00 | 14 | 24343 | 576 | 110564366 |
| Sideroblastic anaemia | 50.53 | 20.00 | 13 | 24344 | 436 | 110564506 |
| Encephalitis | 50.33 | 20.00 | 38 | 24319 | 18801 | 110546141 |
| Liver transplant | 49.89 | 20.00 | 23 | 24334 | 4566 | 110560376 |
| Jarisch-Herxheimer reaction | 49.70 | 20.00 | 16 | 24341 | 1201 | 110563741 |
| Skin disorder | 49.60 | 20.00 | 54 | 24303 | 42859 | 110522083 |
| Rheumatoid arthritis | 48.17 | 20.00 | 5 | 24352 | 299608 | 110265334 |
| Diaphragmatic injury | 48.14 | 20.00 | 10 | 24347 | 126 | 110564816 |
| Liver transplant rejection | 46.90 | 20.00 | 21 | 24336 | 3897 | 110561045 |
| Vomiting | 46.46 | 20.00 | 351 | 24006 | 910324 | 109654618 |
| Arthropathy | 45.70 | 20.00 | 5 | 24352 | 287517 | 110277425 |
| Synovitis | 45.58 | 20.00 | 4 | 24353 | 274088 | 110290854 |
| Blood pressure increased | 45.14 | 20.00 | 3 | 24354 | 258370 | 110306572 |
| Central nervous system vasculitis | 44.89 | 20.00 | 16 | 24341 | 1638 | 110563304 |
| Wheezing | 44.48 | 20.00 | 3 | 24354 | 255227 | 110309715 |
| Adrenocortical insufficiency acute | 44.39 | 20.00 | 21 | 24336 | 4419 | 110560523 |
| Polyneuropathy | 43.65 | 20.00 | 44 | 24313 | 31968 | 110532974 |
| Product dose omission issue | 43.38 | 20.00 | 9 | 24348 | 321773 | 110243169 |
| Splenic embolism | 43.08 | 20.00 | 10 | 24347 | 216 | 110564726 |
| Unmasking of previously unidentified disease | 42.93 | 20.00 | 18 | 24339 | 2850 | 110562092 |
| Ototoxicity | 42.72 | 20.00 | 20 | 24337 | 4111 | 110560831 |
| Pain in extremity | 41.80 | 20.00 | 28 | 24329 | 487090 | 110077852 |
| Musculoskeletal stiffness | 41.72 | 20.00 | 6 | 24351 | 279816 | 110285126 |
| Splenomegaly | 41.59 | 20.00 | 38 | 24319 | 24460 | 110540482 |
| HIV infection | 40.71 | 20.00 | 14 | 24343 | 1289 | 110563653 |
| Toxic optic neuropathy | 40.45 | 20.00 | 14 | 24343 | 1314 | 110563628 |
| Lichenoid keratosis | 40.19 | 20.00 | 22 | 24335 | 6280 | 110558662 |
| Blood bilirubin increased | 39.99 | 20.00 | 65 | 24292 | 75907 | 110489035 |
| Stomatitis | 39.81 | 20.00 | 6 | 24351 | 270236 | 110294706 |
| Bone tuberculosis | 39.79 | 20.00 | 12 | 24345 | 726 | 110564216 |
| Tuberculosis of eye | 39.59 | 20.00 | 8 | 24349 | 87 | 110564855 |
| Hypertension | 39.05 | 20.00 | 33 | 24324 | 510051 | 110054891 |
| Haemophagocytic lymphohistiocytosis | 38.74 | 20.00 | 41 | 24316 | 31518 | 110533424 |
| Abdominal discomfort | 37.49 | 20.00 | 20 | 24337 | 393838 | 110171104 |
| Urinary tract inflammation | 37.46 | 20.00 | 10 | 24347 | 388 | 110564554 |
| Pancytopenia | 37.14 | 20.00 | 116 | 24241 | 209497 | 110355445 |
| Cholestatic liver injury | 36.96 | 20.00 | 22 | 24335 | 7354 | 110557588 |
| Febrile neutropenia | 36.71 | 20.00 | 12 | 24345 | 316755 | 110248187 |
| Cachexia | 36.45 | 20.00 | 27 | 24330 | 12978 | 110551964 |
| Oedematous kidney | 36.24 | 20.00 | 9 | 24348 | 261 | 110564681 |
| Weight increased | 36.16 | 20.00 | 24 | 24333 | 419620 | 110145322 |
| Toxic epidermal necrolysis | 36.12 | 20.00 | 53 | 24304 | 56674 | 110508268 |
| Distributive shock | 35.97 | 20.00 | 20 | 24337 | 5884 | 110559058 |
| Asthma | 35.87 | 20.00 | 6 | 24351 | 250285 | 110314657 |
| Antipsychotic drug level decreased | 35.84 | 20.00 | 13 | 24344 | 1399 | 110563543 |
| Constipation | 35.81 | 20.00 | 17 | 24340 | 357769 | 110207173 |
| Gamma-glutamyltransferase increased | 35.78 | 20.00 | 55 | 24302 | 61254 | 110503688 |
| Hepatic necrosis | 35.71 | 20.00 | 24 | 24333 | 9898 | 110555044 |
| Lymphopenia | 35.45 | 20.00 | 44 | 24313 | 40126 | 110524816 |
| Deafness | 35.12 | 20.00 | 36 | 24321 | 26673 | 110538269 |
| Conductive deafness | 35.06 | 20.00 | 9 | 24348 | 299 | 110564643 |
| Swelling | 34.64 | 20.00 | 17 | 24340 | 351024 | 110213918 |
| Haemolytic anaemia | 34.64 | 20.00 | 32 | 24325 | 20888 | 110544054 |
| Aspergillus infection | 34.54 | 20.00 | 35 | 24322 | 25581 | 110539361 |
| Condition aggravated | 34.52 | 20.00 | 278 | 24079 | 734558 | 109830384 |
| Brain oedema | 33.98 | 20.00 | 38 | 24319 | 31060 | 110533882 |
| Anxiety | 33.62 | 20.00 | 17 | 24340 | 345061 | 110219881 |
| Mycobacterium abscessus infection | 33.45 | 20.00 | 13 | 24344 | 1693 | 110563249 |
| Dry mouth | 33.01 | 20.00 | 3 | 24354 | 199945 | 110364997 |
| Rash morbilliform | 32.93 | 20.00 | 21 | 24336 | 7930 | 110557012 |
| Thalamic infarction | 32.66 | 20.00 | 12 | 24345 | 1340 | 110563602 |
| Contusion | 32.55 | 20.00 | 6 | 24351 | 233355 | 110331587 |
| Treatment noncompliance | 32.53 | 20.00 | 58 | 24299 | 72932 | 110492010 |
| Psoriatic arthropathy | 32.36 | 20.00 | 3 | 24354 | 196758 | 110368184 |
| Face oedema | 31.71 | 20.00 | 38 | 24319 | 33431 | 110531511 |
| Coagulopathy | 31.68 | 20.00 | 42 | 24315 | 40869 | 110524073 |
| Granulomatous lymphadenitis | 31.54 | 20.00 | 9 | 24348 | 448 | 110564494 |
| Mobility decreased | 31.26 | 20.00 | 7 | 24350 | 237415 | 110327527 |
| Discomfort | 31.09 | 20.00 | 5 | 24352 | 214702 | 110350240 |
| Mitochondrial neurogastrointestinal encephalopathy | 30.99 | 20.00 | 5 | 24352 | 12 | 110564930 |
| COVID-19 | 30.75 | 20.00 | 8 | 24349 | 245052 | 110319890 |
| Accelerated hypertension | 30.60 | 20.00 | 10 | 24347 | 787 | 110564155 |
| Cutaneous tuberculosis | 30.52 | 20.00 | 8 | 24349 | 289 | 110564653 |
| Oedematous pancreatitis | 30.30 | 20.00 | 12 | 24345 | 1642 | 110563300 |
| Completed suicide | 30.24 | 20.00 | 8 | 24349 | 242373 | 110322569 |
| Hepatomegaly | 30.23 | 20.00 | 30 | 24327 | 21384 | 110543558 |
| Alopecia | 29.91 | 20.00 | 22 | 24335 | 364731 | 110200211 |
| Disseminated intravascular coagulation | 29.86 | 20.00 | 41 | 24316 | 41245 | 110523697 |
| Respiratory failure | 29.21 | 20.00 | 109 | 24248 | 215223 | 110349719 |
| Feeling abnormal | 29.07 | 20.00 | 3 | 24354 | 180708 | 110384234 |
| Vitamin B1 decreased | 28.99 | 20.00 | 10 | 24347 | 929 | 110564013 |
| Gastrooesophageal reflux disease | 28.92 | 20.00 | 3 | 24354 | 179973 | 110384969 |
| Injection site pain | 28.51 | 20.00 | 3 | 24354 | 177919 | 110387023 |
| Splenic abscess | 28.38 | 20.00 | 10 | 24347 | 990 | 110563952 |
| Injury | 28.37 | 20.00 | 3 | 24354 | 177262 | 110387680 |
| Psoas abscess | 27.88 | 20.00 | 11 | 24346 | 1491 | 110563451 |
| Contraindicated product administered | 27.73 | 20.00 | 10 | 24347 | 248257 | 110316685 |
| Generalised tonic-clonic seizure | 27.71 | 20.00 | 46 | 24311 | 54634 | 110510308 |
| Tuberculous pleurisy | 27.68 | 20.00 | 9 | 24348 | 697 | 110564245 |
| Pulmonary sequestration | 27.68 | 20.00 | 5 | 24352 | 28 | 110564914 |
| Back pain | 27.17 | 20.00 | 25 | 24332 | 370971 | 110193971 |
| Influenza | 26.71 | 20.00 | 3 | 24354 | 169098 | 110395844 |
| Dermatitis exfoliative | 26.21 | 20.00 | 21 | 24336 | 11326 | 110553616 |
| Product prescribing issue | 26.07 | 20.00 | 22 | 24335 | 12750 | 110552192 |
| Type 2 diabetes mellitus | 25.95 | 20.00 | 4 | 24353 | 177228 | 110387714 |
| Encephalopathy | 25.90 | 20.00 | 56 | 24301 | 80999 | 110483943 |
| Infection | 25.83 | 20.00 | 25 | 24332 | 362175 | 110202767 |
| Systemic lupus erythematosus | 25.57 | 20.00 | 12 | 24345 | 254326 | 110310616 |
| Headache | 25.49 | 20.00 | 104 | 24253 | 882273 | 109682669 |
| Hypersensitivity | 25.36 | 20.00 | 31 | 24326 | 403967 | 110160975 |
| Drug hypersensitivity | 25.32 | 20.00 | 38 | 24319 | 454052 | 110110890 |
| Pulmonary granuloma | 25.26 | 20.00 | 12 | 24345 | 2549 | 110562393 |
| Blood cholesterol increased | 25.24 | 20.00 | 5 | 24352 | 184780 | 110380162 |
| Muscle spasms | 25.20 | 20.00 | 15 | 24342 | 278142 | 110286800 |
| Diarrhoea | 25.03 | 20.00 | 148 | 24209 | 1139357 | 109425585 |
| Therapeutic product effect incomplete | 25.02 | 20.00 | 9 | 24348 | 223796 | 110341146 |
| Renal transplant failure | 24.74 | 20.00 | 12 | 24345 | 2668 | 110562274 |
| Oral candidiasis | 24.51 | 20.00 | 39 | 24318 | 44721 | 110520221 |
| Atrial fibrillation | 24.40 | 20.00 | 10 | 24347 | 229632 | 110335310 |
| Drug eruption | 24.38 | 20.00 | 43 | 24314 | 53616 | 110511326 |
| Ill-defined disorder | 24.24 | 20.00 | 3 | 24354 | 156850 | 110408092 |
| Lymph node abscess | 24.07 | 20.00 | 5 | 24352 | 63 | 110564879 |
| Mastitis bacterial | 24.07 | 20.00 | 5 | 24352 | 63 | 110564879 |
| Transplant rejection | 23.45 | 20.00 | 28 | 24329 | 24539 | 110540403 |
| Thrombocytopenia | 23.38 | 20.00 | 144 | 24213 | 348741 | 110216201 |
| Visual acuity reduced | 23.34 | 20.00 | 32 | 24325 | 32141 | 110532801 |
| Pancreatitis acute | 23.23 | 20.00 | 45 | 24312 | 60229 | 110504713 |
| Skin lesion | 22.97 | 20.00 | 41 | 24316 | 51590 | 110513352 |
| Ascites | 22.96 | 20.00 | 58 | 24299 | 92750 | 110472192 |
| Musculoskeletal pain | 22.91 | 20.00 | 6 | 24351 | 183017 | 110381925 |
| Oligohydramnios | 22.89 | 20.00 | 13 | 24344 | 3981 | 110560961 |
| Acid fast bacilli infection | 22.86 | 20.00 | 6 | 24351 | 218 | 110564724 |
| Marrow hyperplasia | 22.70 | 20.00 | 10 | 24347 | 1786 | 110563156 |
| Nicotinic acid deficiency | 22.55 | 20.00 | 6 | 24351 | 230 | 110564712 |
| Subacute hepatic failure | 22.52 | 20.00 | 6 | 24351 | 231 | 110564711 |
| Hereditary optic atrophy | 22.51 | 20.00 | 5 | 24352 | 88 | 110564854 |
| Multiple organ dysfunction syndrome | 22.43 | 20.00 | 79 | 24278 | 151631 | 110413311 |
| Therapeutic product effect decreased | 22.38 | 20.00 | 13 | 24344 | 244303 | 110320639 |
| Premature delivery | 21.52 | 20.00 | 30 | 24327 | 30602 | 110534340 |
| Tuberculoid leprosy | 21.37 | 20.00 | 5 | 24352 | 112 | 110564830 |
| Herbal toxicity | 21.25 | 20.00 | 4 | 24353 | 29 | 110564913 |
| Implant site infection | 21.19 | 20.00 | 10 | 24347 | 2093 | 110562849 |
| Chronic allograft nephropathy | 21.08 | 20.00 | 10 | 24347 | 2116 | 110562826 |
| Testicular mass | 21.04 | 20.00 | 5 | 24352 | 120 | 110564822 |
| Psoriasis | 20.86 | 20.00 | 3 | 24354 | 139990 | 110424952 |
| Acute respiratory distress syndrome | 20.85 | 20.00 | 40 | 24317 | 53158 | 110511784 |
| Hepatosplenomegaly | 20.83 | 20.00 | 15 | 24342 | 6904 | 110558038 |
| Drug intolerance | 20.79 | 20.00 | 36 | 24321 | 406476 | 110158466 |
| Overdose | 20.63 | 20.00 | 13 | 24344 | 233781 | 110331161 |
| Arachnoiditis | 20.63 | 20.00 | 8 | 24349 | 1036 | 110563906 |
| Stevens-Johnson syndrome | 20.55 | 20.00 | 37 | 24320 | 46864 | 110518078 |
| Death | 20.39 | 20.00 | 82 | 24275 | 698787 | 109866155 |
| Glomerulonephritis minimal lesion | 20.28 | 20.00 | 8 | 24349 | 1083 | 110563859 |
| Insomnia | 20.26 | 20.00 | 30 | 24327 | 360560 | 110204382 |
| Ocular icterus | 20.26 | 20.00 | 14 | 24343 | 6039 | 110558903 |
| Renal atrophy | 20.15 | 20.00 | 10 | 24347 | 2336 | 110562606 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J04AK01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Other drugs for treatment of tuberculosis |
| ATC | J04AM05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| ATC | J04AM06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| ATC | J04AM09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| ATC | J04AM10 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| ATC | J04AM11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| ATC | J04AM12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| FDA EPC | N0000175483 | Antimycobacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000995 | Antitubercular Agents |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:50266 | prodrug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
Related Drugs by ATC class:
J04AK Other drugs for treatment of tuberculosis 7 drugs
J04AM Combinations of drugs for treatment of tuberculosis 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute tuberculosis | indication | 25629007 | |
| Tuberculosis of meninges | indication | 58437007 | |
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Nutritional disorder | contraindication | 2492009 | DOID:374 |
| Alcoholism | contraindication | 7200002 | |
| Jaundice | contraindication | 18165001 | |
| Acute hepatitis | contraindication | 37871000 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Gout | contraindication | 90560007 | DOID:13189 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Acute hepatic failure | contraindication | 197270009 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Diabetic - poor control | contraindication | 268519009 | |
| Peripheral nerve disease | contraindication | 302226006 | |
| Porphyria | contraindication | 418470004 | |
| Diabetic peripheral neuropathy | contraindication | 424736006 | |
| Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 | |
| Chronic Hepatic Disease | contraindication | ||
| Prolonged-Severe Nausea and Vomiting | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.39 | acidic |
| pKa2 | 2.14 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Enzyme | IC50 | 6.89 | WOMBAT-PK | |||||
| Carbonic anhydrase 2 | Enzyme | IC50 | 5.77 | WOMBAT-PK | |||||
| Cytochrome P450 3A5 | Enzyme | IC50 | 4.89 | WOMBAT-PK | |||||
| 3-oxoacyl-ACP synthase; Fatty acid synthase Fas; Probable fatty acid synthase Fas (Fatty acid synthetase) | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Cyclopropane mycolic acid synthase 1 | Enzyme | WOMBAT-PK | |||||||
| Amidase; Nicotinamidase; Nicotinamidase/pyrazinamidase; Pyrazinamidase; Pyrazinamidase/nicotinamidase; Pyrazinamidase/nicotinamidase PncA | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4017915 | VUID |
| N0000146266 | NUI |
| D00144 | KEGG_DRUG |
| 4017915 | VANDF |
| C0034239 | UMLSCUI |
| CHEBI:45285 | CHEBI |
| PZA | PDB_CHEM_ID |
| CHEMBL614 | ChEMBL_ID |
| 1046 | PUBCHEM_CID |
| DB00339 | DRUGBANK_ID |
| D011718 | MESH_DESCRIPTOR_UI |
| 786 | INN_ID |
| 7287 | IUPHAR_LIGAND_ID |
| 2KNI5N06TI | UNII |
| 8987 | RXNORM |
| 2368 | MMSL |
| 5390 | MMSL |
| d00117 | MMSL |
| 002849 | NDDF |
| 13592004 | SNOMEDCT_US |
| 387076005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| pyrazinamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0812 | TABLET | 500 mg | ORAL | ANDA | 23 sections |
| PYRAZINAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-735 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| PYRAZINAMIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-735 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Pyrazinamide | Human Prescription Drug Label | 1 | 33342-447 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| Pyrazinamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0521 | TABLET | 500 mg | ORAL | ANDA | 21 sections |
| Pyrazinamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55695-026 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Pyrazinamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-789 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Pyrazinamide | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61748-012 | TABLET | 500 mg | ORAL | ANDA | 22 sections |
| Pyrazinamide | Human Prescription Drug Label | 1 | 70954-484 | TABLET | 500 mg | ORAL | ANDA | 21 sections |